Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K? inhibitor ME-401 in subjects with relapsed / refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy
Lymphoma
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Blinded Drug, ME-401
Reddy, Nishitha
International
Vanderbilt University
10-07-2019
Treatment
VICCPCL1913
NCT03768505

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Histologically confirmed diagnosis of follicular lymphoma (FL) as defined in the World Health Organization (WHO) classification scheme, limited to Grade 1, 2, or 3a

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: